Seroatlas · Human Serome Atlas

ADGRV1

Adhesion G-protein coupled receptor V1

Also known as: AGRV1_HUMAN, DKFZp761P0710, FEB4, GPR98, KIAA0686, MASS1, USH2C, VLGR1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q8WXG9
Gene: ADGRV1
Ensembl: ENSG00000164199
Chromosome: 5
Canonical length: 6306 aa
Protein class: Disease related genes, G-protein coupled receptors, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
Subcellular location: Vesicles,Basal body

OverviewNCBI Gene

This gene encodes a member of the G-protein coupled receptor superfamily. The encoded protein contains a 7-transmembrane receptor domain, binds calcium and is expressed in the central nervous system. Mutations in this gene are associated with Usher syndrome 2 and familial febrile seizures. Several alternatively spliced transcripts have been described. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

6306 residues, UniProt reviewed canonical sequence.

>Q8WXG9|ADGRV1
     1  MSVFLGPGMP SASLLVNLLS ALLILFVFGE TEIRFTGQTE FVVNETSTTV IRLIIERIGE
    61  PANVTAIVSL YGEDAGDFFD TYAAAFIPAG ETNRTVYIAV CDDDLPEPDE TFIFHLTLQK
   121  PSANVKLGWP RTVTVTILSN DNAFGIISFN MLPSIAVSEP KGRNESMPLT LIREKGTYGM
   181  VMVTFEVEGG PNPPDEDLSP VKGNITFPPG RATVIYNLTV LDDEVPENDE IFLIQLKSVE
   241  GGAEINTSRN SIEIIIKKND SPVRFLQSIY LVPEEDHILI IPVVRGKDNN GNLIGSDEYE
   301  VSISYAVTTG NSTAHAQQNL DFIDLQPNTT VVFPPFIHES HLKFQIVDDT IPEIAESFHI
   361  MLLKDTLQGD AVLISPSVVQ VTIKPNDKPY GVLSFNSVLF ERTVIIDEDR ISRYEEITVV
   421  RNGGTHGNVS ANWVLTRNST DPSPVTADIR PSSGVLHFAQ GQMLATIPLT VVDDDLPEEA
   481  EAYLLQILPH TIRGGAEVSE PAELLFYIQD SDDVYGLITF FPMENQKIES SPGERYLSLS
   541  FTRLGGTKGD VRLLYSVLYI PAGAVDPLQA KEGILNISRR NDLIFPEQKT QVTTKLPIRN
   601  DAFLQNGAHF LVQLETVELL NIIPLIPPIS PRFGEICNIS LLVTPAIANG EIGFLSNLPI
   661  ILHEPEDFAA EVVYIPLHRD GTDGQATVYW SLKPSGFNSK AVTPDDIGPF NGSVLFLSGQ
   721  SDTTINITIK GDDIPEMNET VTLSLDRVNV ENQVLKSGYT SRDLIILEND DPGGVFEFSP
   781  ASRGPYVIKE GESVELHIIR SRGSLVKQFL HYRVEPRDSN EFYGNTGVLE FKPGEREIVI
   841  TLLARLDGIP ELDEHYWVVL SSHGERESKL GSATIVNITI LKNDDPHGII EFVSDGLIVM
   901  INESKGDAIY SAVYDVVRNR GNFGDVSVSW VVSPDFTQDV FPVQGTVVFG DQEFSKNITI
   961  YSLPDEIPEE MEEFTVILLN GTGGAKVGNR TTATLRIRRN DDPIYFAEPR VVRVQEGETA
  1021  NFTVLRNGSV DVTCMVQYAT KDGKATARER DFIPVEKGET LIFEVGSRQQ SISIFVNEDG
  1081  IPETDEPFYI ILLNSTGDTV VYQYGVATVI IEANDDPNGI FSLEPIDKAV EEGKTNAFWI
  1141  LRHRGYFGSV SVSWQLFQND SALQPGQEFY ETSGTVNFMD GEEAKPIILH AFPDKIPEFN
  1201  EFYFLKLVNI SGGSPGPGGQ LAETNLQVTV MVPFNDDPFG VFILDPECLE REVAEDVLSE
  1261  DDMSYITNFT ILRQQGVFGD VQLGWEILSS EFPAGLPPMI DFLLVGIFPT TVHLQQHMRR
  1321  HHSGTDALYF TGLEGAFGTV NPKYHPSRNN TIANFTFSAW VMPNANTNGF IIAKDDGNGS
  1381  IYYGVKIQTN ESHVTLSLHY KTLGSNATYI AKTTVMKYLE ESVWLHLLII LEDGIIEFYL
  1441  DGNAMPRGIK SLKGEAITDG PGILRIGAGI NGNDRFTGLM QDVRSYERKL TLEEIYELHA
  1501  MPAKSDLHPI SGYLEFRQGE TNKSFIISAR DDNDEEGEEL FILKLVSVYG GARISEENTT
  1561  ARLTIQKSDN ANGLFGFTGA CIPEIAEEGS TISCVVERTR GALDYVHVFY TISQIETDGI
  1621  NYLVDDFANA SGTITFLPWQ RSEVLNIYVL DDDIPELNEY FRVTLVSAIP GDGKLGSTPT
  1681  SGASIDPEKE TTDITIKASD HPYGLLQFST GLPPQPKDAM TLPASSVPHI TVEEEDGEIR
  1741  LLVIRAQGLL GRVTAEFRTV SLTAFSPEDY QNVAGTLEFQ PGERYKYIFI NITDNSIPEL
  1801  EKSFKVELLN LEGGVAELFR VDGSGSGDGD MEFFLPTIHK RASLGVASQI LVTIAASDHA
  1861  HGVFEFSPES LFVSGTEPED GYSTVTLNVI RHHGTLSPVT LHWNIDSDPD GDLAFTSGNI
  1921  TFEIGQTSAN ITVEILPDED PELDKAFSVS VLSVSSGSLG AHINATLTVL ASDDPYGIFI
  1981  FSEKNRPVKV EEATQNITLS IIRLKGLMGK VLVSYATLDD MEKPPYFPPN LARATQGRDY
  2041  IPASGFALFG ANQSEATIAI SILDDDEPER SESVFIELLN STLVAKVQSR SIPNSPRLGP
  2101  KVETIAQLII IANDDAFGTL QLSAPIVRVA ENHVGPIINV TRTGGAFADV SVKFKAVPIT
  2161  AIAGEDYSIA SSDVVLLEGE TSKAVPIYVI NDIYPELEES FLVQLMNETT GGARLGALTE
  2221  AVIIIEASDD PYGLFGFQIT KLIVEEPEFN SVKVNLPIIR NSGTLGNVTV QWVATINGQL
  2281  ATGDLRVVSG NVTFAPGETI QTLLLEVLAD DVPEIEEVIQ VQLTDASGGG TIGLDRIANI
  2341  IIPANDDPYG TVAFAQMVYR VQEPLERSSC ANITVRRSGG HFGRLLLFYS TSDIDVVALA
  2401  MEEGQDLLSY YESPIQGVPD PLWRTWMNVS AVGEPLYTCA TLCLKEQACS AFSFFSASEG
  2461  PQCFWMTSWI SPAVNNSDFW TYRKNMTRVA SLFSGQAVAG SDYEPVTRQW AIMQEGDEFA
  2521  NLTVSILPDD FPEMDESFLI SLLEVHLMNI SASLKNQPTI GQPNISTVVI ALNGDAFGVF
  2581  VIYNISPNTS EDGLFVEVQE QPQTLVELMI HRTGGSLGQV AVEWRVVGGT ATEGLDFIGA
  2641  GEILTFAEGE TKKTVILTIL DDSEPEDDES IIVSLVYTEG GSRILPSSDT VRVNILANDN
  2701  VAGIVSFQTA SRSVIGHEGE ILQFHVIRTF PGRGNVTVNW KIIGQNLELN FANFSGQLFF
  2761  PEGSLNTTLF VHLLDDNIPE EKEVYQVILY DVRTQGVPPA GIALLDAQGY AAVLTVEASD
  2821  EPHGVLNFAL SSRFVLLQEA NITIQLFINR EFGSLGAINV TYTTVPGMLS LKNQTVGNLA
  2881  EPEVDFVPII GFLILEEGET AAAINITILE DDVPELEEYF LVNLTYVGLT MAASTSFPPR
  2941  LDSEGLTAQV IIDANDGARG VIEWQQSRFE VNETHGSLTL VAQRSREPLG HVSLFVYAQN
  3001  LEAQVGLDYI FTPMILHFAD GERYKNVNIM ILDDDIPEGD EKFQLILTNP SPGLELGKNT
  3061  IALIIVLAND DGPGVLSFNN SEHFFLREPT ALYVQESVAV LYIVREPAQG LFGTVTVQFI
  3121  VTEVNSSNES KDLTPSKGYI VLEEGVRFKA LQISAILDTE PEMDEYFVCT LFNPTGGARL
  3181  GVHVQTLITV LQNQAPLGLF SISAVENRAT SIDIEEANRT VYLNVSRTNG IDLAVSVQWE
  3241  TVSETAFGMR GMDVVFSVFQ SFLDESASGW CFFTLENLIY GIMLRKSSVT VYRWQGIFIP
  3301  VEDLNIENPK TCEAFNIGFS PYFVITHEER NEEKPSLNSV FTFTSGFKLF LVQTIIILES
  3361  SQVRYFTSDS QDYLIIASQR DDSELTQVFR WNGGSFVLHQ KLPVRGVLTV ALFNKGGSVF
  3421  LAISQANARL NSLLFRWSGS GFINFQEVPV SGTTEVEALS SANDIYLIFA ENVFLGDQNS
  3481  IDIFIWEMGQ SSFRYFQSVD FAAVNRIHSF TPASGIAHIL LIGQDMSALY CWNSERNQFS
  3541  FVLEVPSAYD VASVTVKSLN SSKNLIALVG AHSHIYELAY ISSHSDFIPS SGELIFEPGE
  3601  REATIAVNIL DDTVPEKEES FKVQLKNPKG GAEIGINDSV TITILSNDDA YGIVAFAQNS
  3661  LYKQVEEMEQ DSLVTLNVER LKGTYGRITI AWEADGSISD IFPTSGVILF TEGQVLSTIT
  3721  LTILADNIPE LSEVVIVTLT RITTEGVEDS YKGATIDQDR SKSVITTLPN DSPFGLVGWR
  3781  AASVFIRVAE PKENTTTLQL QIARDKGLLG DIAIHLRAQP NFLLHVDNQA TENEDYVLQE
  3841  TIIIMKENIK EAHAEVSILP DDLPELEEGF IVTITEVNLV NSDFSTGQPS VRRPGMEIAE
  3901  IMIEENDDPR GIFMFHVTRG AGEVITAYEV PPPLNVLQVP VVRLAGSFGA VNVYWKASPD
  3961  SAGLEDFKPS HGILEFADKQ VTAMIEITII DDAEFELTET FNISLISVAG GGRLGDDVVV
  4021  TVVIPQNDSP FGVFGFEEKT VMIDESLSSD DPDSYVTLTV VRSPGGKGTV RLEWTIDEKA
  4081  KHNLSPLNGT LHFDETESQK TIVLHTLQDT VLEEDRRFTI QLISIDEVEI SPVKGSASII
  4141  IRGDKRASGE VGIAPSSRHI LIGEPSAKYN GTAIISLVRG PGILGEVTVF WRIFPPSVGE
  4201  FAETSGKLTM RDEQSAVIVV IQALNDDIPE EKSFYEFQLT AVSEGGVLSE SSSTANITVV
  4261  ASDSPYGRFA FSHEQLRVSE AQRVNITIIR SSGDFGHVRL WYKTMSGTAE AGLDFVPAAG
  4321  ELLFEAGEMR KSLHVEILDD DYPEGPEEFS LTITKVELQG RGYDFTIQEN GLQIDQPPEI
  4381  GNISIVRIII MKNDNAEGII EFDPKYTAFE VEEDVGLIMI PVVRLHGTYG YVTADFISQS
  4441  SSASPGGVDY ILHGSTVTFQ HGQNLSFINI SIIDDNESEF EEPIEILLTG ATGGAVLGRH
  4501  LVSRIIIAKS DSPFGVIRFL NQSKISIANP NSTMILSLVL ERTGGLLGEI QVNWETVGPN
  4561  SQEALLPQNR DIADPVSGLF YFGEGEGGVR TIILTIYPHE EIEVEETFII KLHLVKGEAK
  4621  LDSRAKDVTL TIQEFGDPNG VVQFAPETLS KKTYSEPLAL EGPLLITFFV RRVKGTFGEI
  4681  MVYWELSSEF DITEDFLSTS GFFTIADGES EASFDVHLLP DEVPEIEEDY VIQLVSVEGG
  4741  AELDLEKSIT WFSVYANDDP HGVFALYSDR QSILIGQNLI RSIQINITRL AGTFGDVAVG
  4801  LRISSDHKEQ PIVTENAERQ LVVKDGATYK VDVVPIKNQV FLSLGSNFTL QLVTVMLVGG
  4861  RFYGMPTILQ EAKSAVLPVS EKAANSQVGF ESTAFQLMNI TAGTSHVMIS RRGTYGALSV
  4921  AWTTGYAPGL EIPEFIVVGN MTPTLGSLSF SHGEQRKGVF LWTFPSPGWP EAFVLHLSGV
  4981  QSSAPGGAQL RSGFIVAEIE PMGVFQFSTS SRNIIVSEDT QMIRLHVQRL FGFHSDLIKV
  5041  SYQTTAGSAK PLEDFEPVQN GELFFQKFQT EVDFEITIIN DQLSEIEEFF YINLTSVEIR
  5101  GLQKFDVNWS PRLNLDFSVA VITILDNDDL AGMDISFPET TVAVAVDTTL IPVETESTTY
  5161  LSTSKTTTIL QPTNVVAIVT EATGVSAIPE KLVTLHGTPA VSEKPDVATV TANVSIHGTF
  5221  SLGPSIVYIE EEMKNGTFNT AEVLIRRTGG FTGNVSITVK TFGERCAQME PNALPFRGIY
  5281  GISNLTWAVE EEDFEEQTLT LIFLDGERER KVSVQILDDD EPEGQEFFYV FLTNPQGGAQ
  5341  IVEEKDDTGF AAFAMVIITG SDLHNGIIGF SEESQSGLEL REGAVMRRLH LIVTRQPNRA
  5401  FEDVKVFWRV TLNKTVVVLQ KDGVNLVEEL QSVSGTTTCT MGQTKCFISI ELKPEKVPQV
  5461  EVYFFVELYE ATAGAAINNS ARFAQIKILE SDESQSLVYF SVGSRLAVAH KKATLISLQV
  5521  ARDSGTGLMM SVNFSTQELR SAETIGRTII SPAISGKDFV ITEGTLVFEP GQRSTVLDVI
  5581  LTPETGSLNS FPKRFQIVLF DPKGGARIDK VYGTANITLV SDADSQAIWG LADQLHQPVN
  5641  DDILNRVLHT ISMKVATENT DEQLSAMMHL IEKITTEGKI QAFSVASRTL FYEILCSLIN
  5701  PKRKDTRGFS HFAEVTENFA FSLLTNVTCG SPGEKSKTIL DSCPYLSILA LHWYPQQING
  5761  HKFEGKEGDY IRIPERLLDV QDAEIMAGKS TCKLVQFTEY SSQQWFISGN NLPTLKNKVL
  5821  SLSVKGQSSQ LLTNDNEVLY RIYAAEPRII PQTSLCLLWN QAAASWLSDS QFCKVVEETA
  5881  DYVECACSHM SVYAVYARTD NLSSYNEAFF TSGFICISGL CLAVLSHIFC ARYSMFAAKL
  5941  LTHMMAASLG TQILFLASAY ASPQLAEESC SAMAAVTHYL YLCQFSWMLI QSVNFWYVLV
  6001  MNDEHTERRY LLFFLLSWGL PAFVVILLIV ILKGIYHQSM SQIYGLIHGD LCFIPNVYAA
  6061  LFTAALVPLT CLVVVFVVFI HAYQVKPQWK AYDDVFRGRT NAAEIPLILY LFALISVTWL
  6121  WGGLHMAYRH FWMLVLFVIF NSLQGLYVFM VYFILHNQMC CPMKASYTVE MNGHPGPSTA
  6181  FFTPGSGMPP AGGEISKSTQ NLIGAMEEVP PDWERASFQQ GSQASPDLKP SPQNGATFPS
  6241  SGGYGQGSLI ADEESQEFDD LIFALKTGAG LSVSDNESGQ GSQEGGTLTD SQIVELRRIP
  6301  IADTHL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ADGRV1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0
Highest tissue expression: 495 nTPM

Expression across tissuesHPA

Tissue

adrenal gland: 495 nTPM
basal ganglia: 45 nTPM
liver: 40 nTPM
amygdala: 31 nTPM
cerebral cortex: 27 nTPM
kidney: 20 nTPM

Single-cell type

pituicytes/fscs: 3,636 nCPM
astrocytes: 3,318 nCPM
choroid plexus epithelial cells: 1,386 nCPM
ependymal cells: 1,045 nCPM
cone photoreceptor cells: 932 nCPM
adrenal cortex cells: 789 nCPM

Immune cell

neutrophil: 4.6 nTPM
basophil: 3.2 nTPM
naive B-cell: 3 nTPM
eosinophil: 2.8 nTPM
MAIT T-cell: 1.7 nTPM
naive CD4 T-cell: 1.7 nTPM

Brain region

basal ganglia: 92 nTPM
cerebral cortex: 75 nTPM
hippocampal formation: 71 nTPM
amygdala: 69 nTPM
white matter: 47 nTPM
choroid plexus: 40 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ADGRV1.

Disease | AllUniProt

Conditions ADGRV1 is implicated in, by any mechanism.

Usher syndrome 2C (USH2C) MIM:605472
Febrile seizures, familial, 4 (FEB4) MIM:604352

Disease | GeneticClinVar

661 pathogenic / likely-pathogenic of 7,121 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on ADGRV1 was assayed in.

human immunodeficiency virus infectious disease T cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.52
gnomAD pLI: 0
DepMap mean gene effect: 0
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ADGRV1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ADGRV1 as an antibody target. Whether an autoantibody or antibody against ADGRV1 could matter depends on whether native ADGRV1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ADGRV1 is annotated at the cell surface, where native ADGRV1 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label ADGRV1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...